Nielsen PB, et al. - In patients with atrial fibrillation (AF) suffering an intracerebral hemorrhage, researchers examined the relative efficacy and safety of non-vitamin K antagonist oral anticoagulant (NOAC) vs warfarin. Participants in the study were intracerebral hemorrhage patients with AF,who subsequently claimed an OAC prescription. Of 622 intracerebral hemorrhage AF patients, 274 claimed a prescription for warfarin and 348 claimed a prescription for NOAC. The risk was 7.00% for warfarin and 5.07% for NOACs for recurrent intracerebral hemorrhage. According to this nationwide observational cohort study, a non-significant lower risk of ischemic stroke and recurrent intracerebral hemorrhage was related to NOACs vs warfarin. The results complement current recommendations to choose a NOAC agent for treatment of stroke prophylaxis in AF patients, including those with intracerebral hemorrhage.